Sintx Technologies, INC 8-K filings

SINTX Technologies announced it has regained compliance with Nasdaq's minimum stockholders equity requirement, closing a previously disclosed deficiency matter.

SINTX Technologies provides a mid-year 2026 business update, detailing progress in its SiNAPTIC Foot & Ankle Implant System commercialization, industrial order fulfillment, and strategic platform expansion.

SINTX Technologies has engaged Southern Metrics Consulting, led by MedTech veteran Chris Lyons, to manage a new program focused on identifying and pursuing strategic opportunities to enhance stockholder value.

SINTX Technologies finalized a letter agreement to resolve outstanding warrants and abeyance shares, impacting its capital structure and equity position.

SINTX Technologies announced a $4.5 million private placement of units, including common stock and warrants, to fund general corporate purposes.

SINTX Technologies received a notice from Nasdaq for failing to meet minimum stockholders equity requirements, with 45 days to submit a compliance plan.

SINTX Technologies signs a supply agreement with Evonik Corporation to manufacture its proprietary silicon nitride-PEEK compound for AI-assisted, 3D-printed patient-specific implants.

SINTX Technologies reports pivotal Q3 2025 results, driven by FDA clearance for its SINAPTIC Foot & Ankle system, initial OsseoSculpt revenue, and significant operational cost reductions.

SINTX Technologies, Inc. has entered into an At The Market Offering Agreement to sell up to $6.4 million of common stock.

SINTX Technologies secures $3.8 million in gross proceeds by inducing existing warrant holders to exercise, issuing new warrants and incurring significant fees.

SINTX Technologies announced the appointment of Kevin Trask as Chief Financial Officer and the approval of its 2025 Equity Incentive Plan by stockholders.

SINTX Technologies announced the submission of a 510(k) premarket notification to the FDA for novel silicon nitride osteotomy wedges, marking its official entry into the foot and ankle reconstruction market.

SINTX Technologies, Inc. has acquired substantially all surgical business assets of SiNAPTIC Surgical, LLC, including intellectual property and product designs for foot and ankle implants, in a deal involving common shares, performance-based warrants, and a private placement.

SINTX Technologies is expanding into the agribiotech sector with a new subsidiary and patent focused on antimicrobial applications, targeting a market projected to reach $10.36 billion by 2030.

SINTX Technologies is refocusing on high-growth medical markets, highlighting a strategic shift towards medical device commercialization and reporting its Q1 2025 financial results.

SINTX Technologies has entered into new executive employment agreements with its CEO, Eric K. Olson, and CIO, Gregg Honigblum, replacing previous agreements and outlining compensation, bonus structures, and severance terms.

SINTX Technologies announces the appointment of five new directors and the resignation of five existing directors, effective April 3, 2025.

SINTX Technologies announced the appointment of Eric K. Olson as Chairman of the Board, effective March 7, 2025, with B. Sonny Bal remaining on the Board.

SINTX Technologies has successfully completed a $5 million private placement to advance its work in medical-grade advanced ceramics.

SINTX Technologies divests its wholly-owned subsidiary, Technology Assessment and Transfer, Inc. (TA&T), to Tethon Corporation in exchange for the assumption of TA&T's outstanding liabilities.

SINTX Technologies held its 2024 annual meeting, electing a director, ratifying the auditor, approving executive compensation, increasing share authorization for the equity plan, and approving meeting adjournments if needed.

SINTX Technologies has amended its CEO's severance agreement, increasing potential payouts, and established a new change in control agreement for its Chief Strategy Officer.

SINTX Technologies has appointed its current CEO, Eric K. Olson, to its Board of Directors, effective November 22, 2024.

SINTX Technologies has appointed Gregg Honigblum as Chief Strategy Officer to lead strategic growth initiatives and enhance investor relations.

SINTX Technologies has authorized a stock repurchase program to buy back up to $500,000 of its common stock, representing approximately 20% of outstanding shares.

SINTX Technologies has amended its CEO's employment agreement, extending the term and adding a change of control agreement with specific severance and vesting terms.

SINTX Technologies has entered into a new six-month employment agreement with CEO Eric K. Olson, including a $25,000 bonus and a $350,000 annual salary.

SINTX Technologies has appointed Eric K. Olson as its new Chief Executive Officer and President, succeeding B. Sonny Bal, who will now serve as Chairman of the Board.

SINTX Technologies has resumed its at-the-market offering, aiming to raise up to $3.1 million for working capital and general corporate purposes.

SINTX Technologies has successfully regained compliance with Nasdaq's minimum bid price requirement, closing a previously announced listing matter.